Zastosowanie linagliptyny u chorych na cukrzycę potransplantacyjną. Ocena bezpieczeństwa i skuteczności leczenia na podstawie opisu serii przypadków klinicznych

Abstract

Post-transplantation diabetes (PTDM) is a frequent problem in patients after solid organ transplantation. PTDM is more common in recipients with risk fac­tors of diabetes mellitus, may also be associated with the immunosuppressive regimen used. No spe­cific guidelines for diagnosis and pharmacotherapy of this type of diabetes have been established, there­fore those for the treatment of diabetes in general population are followed. The basis of non-pharma­cological treatment are diet, weight loss, regular physical exercise. In the choice of antidiabetic therapy in PTDM, additionally graft function and pos­sible drug interactions (especially with immunosup­pressive therapy) should be considered. Linagliptin, a dipeptidyl peptidase-4 inhibitor belonging to a rela­tively new group of diabetic drugs, appears to be an effective and safe drug in monotherapy, but also in combination with other hypoglycemic medications in patients with PTDM.